Key performance indicators (KPIs) measure how effective your company is at achieving its goals. Learn how to find the right ...

For people with relapsed or refractory multiple myeloma (RRMM), teclistamab plus daratumumab increases survival compared to daratumumab plus dexamethasone and either pomalidomide or bortezomib, ...

Pharma Logistics BI is a comprehensive pharmaceutical supply chain management dashboard built with Power BI. It provides real-time visibility into orders, transportation, inventory, quality compliance ...

Dr. Rahul Banerjee discusses major advances in bispecific antibodies presented at ASH 2025 for multiple myeloma, including the MajesTEC-3 study (teclistamab plus daratumumab), the IFM2021-01 study for ...

Tommy Egan is on one this season, and it may be entertaining as hell, but his enemies list is growing by the second. And I didn’t think it could get any longer than it already was. At the end of the ...

Advances in MM management have improved survival, but challenges remain for patients progressing after three therapy lines. New therapies like CAR T-cell and bispecific antibodies require integration ...

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology. Education and attentive monitoring of adverse effects ...

1 Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 2 Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of ...

An expert discusses how treatment guidelines and institutional pathways are evolving to integrate CAR T-cell therapies and bispecific antibodies for relapsed/refractory multiple myeloma (R/R MM), ...